Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Candel Therapeutics (CADL) Interest & Investment Income (2020 - 2025)

Candel Therapeutics' Interest & Investment Income history spans 4 years, with the latest figure at $415000.0 for Q4 2023.

  • On a quarterly basis, Interest & Investment Income fell 48.38% to $415000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $2.1 million, a 99.71% increase, with the full-year FY2025 number at $3.9 million, up 260.5% from a year prior.
  • Interest & Investment Income hit $415000.0 in Q4 2023 for Candel Therapeutics, down from $502000.0 in the prior quarter.
  • Over the last five years, Interest & Investment Income for CADL hit a ceiling of $804000.0 in Q4 2022 and a floor of -$175000.0 in Q1 2022.
  • Historically, Interest & Investment Income has averaged $217000.0 across 4 years, with a median of $70000.0 in 2022.
  • The widest YoY moves for Interest & Investment Income: up 7409.09% in 2022, down 1358.33% in 2022.
  • Tracing CADL's Interest & Investment Income over 4 years: stood at $49000.0 in 2020, then crashed by 122.45% to -$11000.0 in 2021, then soared by 7409.09% to $804000.0 in 2022, then plummeted by 48.38% to $415000.0 in 2023.
  • Business Quant data shows Interest & Investment Income for CADL at $415000.0 in Q4 2023, $502000.0 in Q3 2023, and $453000.0 in Q2 2023.